Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial)
Abciximab therapy during primary percutaneous coronary intervention (PCI) has shown to ameliorate left ventricular (LV) function recovery in patients with ST elevated myocardial infarction. High-dose bolus tirofiban has similar effect on platelet inhibition. Whether this is associated with comparabl...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2009-03, Vol.103 (6), p.785-790 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 790 |
|---|---|
| container_issue | 6 |
| container_start_page | 785 |
| container_title | The American journal of cardiology |
| container_volume | 103 |
| creator | Taglieri, Nevio, MD Saia, Francesco, MD, PhD Guiducci, Vincenzo, MD Tondi, Stefano, MD Conrotto, Federico, MD Marrozzini, Cinzia, MD Rocchi, Guido, MD Biagini, Elena, MD, PhD Reggiani, Maria Letizia Bacchi, MSc Giacometti, Paola, MD Piovaccari, Giancarlo, MD Manari, Antonio, MD Marzocchi, Antonio, MD |
| description | Abciximab therapy during primary percutaneous coronary intervention (PCI) has shown to ameliorate left ventricular (LV) function recovery in patients with ST elevated myocardial infarction. High-dose bolus tirofiban has similar effect on platelet inhibition. Whether this is associated with comparable efficacy on LV function recovery remains unclear. We sought to evaluate the impact on LV function of high-dose bolus tirofiban or abciximab in patients undergoing primary PCI with the predictors of favorable (≥50%) LV ejection fraction (EF) and LV function recovery at 30 days. We studied 314 patients (abciximab n = 154; tirofiban n = 160) undergoing primary PCI in the randomized Facilitated Angioplasty with Tirofiban or Abciximab (FATA) trial. LVEF was assessed within 48 hours and at 30 days after primary PCI. In patients with systolic dysfunction at baseline, LV function recovery was defined by either increase of LVEF ≥10% compared with baseline or LVEF ≥50%. Similar LVEF was observed in the 2 groups postprocedure (abciximab 49.7 ± 10.1% vs tirofiban 49.3 ± 10.1%, p = 0.9) and at 30 days (abciximab 53.1 ± 9.8% vs tirofiban 52.5 ± 10.2%, p = 0.6). Independent predictors of 30-day LVEF ≥50% were preprocedure Thrombolysis In Myocardial Infarction flow class >0 (odds ratio = 2.4, 95% confidence interval 1.32 to 4.34), anterior location (odds ratio = 0.25, 95% confidence interval 0.15 to 0.42), and age (odds ratio = 0.97, 95% confidence interval 0.95 to 0.99). Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 was the only predictor of LV function recovery (odds ratio = 6.73, 95% confidence interval 2.69 to 16.88). In conclusion, this study showed no difference in LV function recovery in patients undergoing primary PCI treated either with abciximab or high-dose bolus tirofiban. Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 seems to be the most important predictor of favorable LVEF and LV function recovery at 30 days. |
| doi_str_mv | 10.1016/j.amjcard.2008.11.029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67000796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002914908020845</els_id><sourcerecordid>1663594631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-e73a955f67c7518306cfab78508c1c777ee95657a04d926f6ed55dde39ff28613</originalsourceid><addsrcrecordid>eNqFksGO0zAQhiMEYpeFRwBZSCA4pNhJHccXUFRtoVIRlbbAASHLdcasS2oX2yn0oXkHnG21lfbCybLz_f9MZv4se0rwiGBSvVmP5GatpG9HBcb1iJARLvi97JzUjOeEk_J-do4xLnJOxvwsexTCOl0JodXD7IzwoqpZWZxnf-egI_oCNnqj-k56NO2tisZZ1OgIHl0t88sOdvLm6ePeDSWN7NDMaukPoLFokb4nj4CWHmSEFn018RotvNlIv0cL8KqP0oLrA5o47-zwOrPJf5dUg4e0LWpWyvxJihVyHi2Nd9qspEWvtHcbFK8BTaUynYk3BRr7w7htJ0Pco99DsZMgqU9W36bNsvme-kpNv36cPdCyC_DkeF5kn6eXy8mHfP7p_WzSzHM1ZjTmwErJKdUVU4ySusSV0nLFaoprRRRjDIDTijKJx22apK6gpbRtoeRaF3VFyovs5cF3692vHkIUGxMUdN1hBqJiaReMVwl8fgdcu97b1JsoSlxyRmiRIHqAlHcheNBiexisIFgMYRBrcQyDGMIgCBEpDEn37GjerzbQnlTH7SfgxRGQQclOe2mVCbdcQYqaczZw7w4cpJntDHgRVFq3gtZ4UFG0zvy3lbd3HFRnrElFf8Iewu1PExEKgcXVkNwhuLjGBa7HtPwHZg3uJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230397152</pqid></control><display><type>article</type><title>Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Taglieri, Nevio, MD ; Saia, Francesco, MD, PhD ; Guiducci, Vincenzo, MD ; Tondi, Stefano, MD ; Conrotto, Federico, MD ; Marrozzini, Cinzia, MD ; Rocchi, Guido, MD ; Biagini, Elena, MD, PhD ; Reggiani, Maria Letizia Bacchi, MSc ; Giacometti, Paola, MD ; Piovaccari, Giancarlo, MD ; Manari, Antonio, MD ; Marzocchi, Antonio, MD</creator><creatorcontrib>Taglieri, Nevio, MD ; Saia, Francesco, MD, PhD ; Guiducci, Vincenzo, MD ; Tondi, Stefano, MD ; Conrotto, Federico, MD ; Marrozzini, Cinzia, MD ; Rocchi, Guido, MD ; Biagini, Elena, MD, PhD ; Reggiani, Maria Letizia Bacchi, MSc ; Giacometti, Paola, MD ; Piovaccari, Giancarlo, MD ; Manari, Antonio, MD ; Marzocchi, Antonio, MD ; FATA Investigators ; FATA Trial Investigators</creatorcontrib><description>Abciximab therapy during primary percutaneous coronary intervention (PCI) has shown to ameliorate left ventricular (LV) function recovery in patients with ST elevated myocardial infarction. High-dose bolus tirofiban has similar effect on platelet inhibition. Whether this is associated with comparable efficacy on LV function recovery remains unclear. We sought to evaluate the impact on LV function of high-dose bolus tirofiban or abciximab in patients undergoing primary PCI with the predictors of favorable (≥50%) LV ejection fraction (EF) and LV function recovery at 30 days. We studied 314 patients (abciximab n = 154; tirofiban n = 160) undergoing primary PCI in the randomized Facilitated Angioplasty with Tirofiban or Abciximab (FATA) trial. LVEF was assessed within 48 hours and at 30 days after primary PCI. In patients with systolic dysfunction at baseline, LV function recovery was defined by either increase of LVEF ≥10% compared with baseline or LVEF ≥50%. Similar LVEF was observed in the 2 groups postprocedure (abciximab 49.7 ± 10.1% vs tirofiban 49.3 ± 10.1%, p = 0.9) and at 30 days (abciximab 53.1 ± 9.8% vs tirofiban 52.5 ± 10.2%, p = 0.6). Independent predictors of 30-day LVEF ≥50% were preprocedure Thrombolysis In Myocardial Infarction flow class >0 (odds ratio = 2.4, 95% confidence interval 1.32 to 4.34), anterior location (odds ratio = 0.25, 95% confidence interval 0.15 to 0.42), and age (odds ratio = 0.97, 95% confidence interval 0.95 to 0.99). Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 was the only predictor of LV function recovery (odds ratio = 6.73, 95% confidence interval 2.69 to 16.88). In conclusion, this study showed no difference in LV function recovery in patients undergoing primary PCI treated either with abciximab or high-dose bolus tirofiban. Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 seems to be the most important predictor of favorable LVEF and LV function recovery at 30 days.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2008.11.029</identifier><identifier>PMID: 19268732</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Angioplasty, Balloon, Coronary ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Cardiology ; Cardiology. Vascular system ; Cardiovascular ; Combined Modality Therapy ; Coronary heart disease ; Coronary vessels ; Diseases of the cardiovascular system ; Drug dosages ; Drug therapy ; Electrocardiography ; Female ; Heart ; Heart attacks ; Humans ; Immunoglobulin Fab Fragments - pharmacology ; Immunoglobulin Fab Fragments - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - diagnosis ; Myocardial Infarction - drug therapy ; Myocardial Infarction - therapy ; Myocarditis. Cardiomyopathies ; Pharmacology ; Platelet Aggregation Inhibitors - pharmacology ; Platelet Aggregation Inhibitors - therapeutic use ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Treatment Outcome ; Tyrosine - analogs & derivatives ; Tyrosine - pharmacology ; Tyrosine - therapeutic use ; Ventricular Function, Left - drug effects</subject><ispartof>The American journal of cardiology, 2009-03, Vol.103 (6), p.785-790</ispartof><rights>Elsevier Inc.</rights><rights>2009 Elsevier Inc.</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Mar 15, 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-e73a955f67c7518306cfab78508c1c777ee95657a04d926f6ed55dde39ff28613</citedby><cites>FETCH-LOGICAL-c475t-e73a955f67c7518306cfab78508c1c777ee95657a04d926f6ed55dde39ff28613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914908020845$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21289972$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19268732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taglieri, Nevio, MD</creatorcontrib><creatorcontrib>Saia, Francesco, MD, PhD</creatorcontrib><creatorcontrib>Guiducci, Vincenzo, MD</creatorcontrib><creatorcontrib>Tondi, Stefano, MD</creatorcontrib><creatorcontrib>Conrotto, Federico, MD</creatorcontrib><creatorcontrib>Marrozzini, Cinzia, MD</creatorcontrib><creatorcontrib>Rocchi, Guido, MD</creatorcontrib><creatorcontrib>Biagini, Elena, MD, PhD</creatorcontrib><creatorcontrib>Reggiani, Maria Letizia Bacchi, MSc</creatorcontrib><creatorcontrib>Giacometti, Paola, MD</creatorcontrib><creatorcontrib>Piovaccari, Giancarlo, MD</creatorcontrib><creatorcontrib>Manari, Antonio, MD</creatorcontrib><creatorcontrib>Marzocchi, Antonio, MD</creatorcontrib><creatorcontrib>FATA Investigators</creatorcontrib><creatorcontrib>FATA Trial Investigators</creatorcontrib><title>Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Abciximab therapy during primary percutaneous coronary intervention (PCI) has shown to ameliorate left ventricular (LV) function recovery in patients with ST elevated myocardial infarction. High-dose bolus tirofiban has similar effect on platelet inhibition. Whether this is associated with comparable efficacy on LV function recovery remains unclear. We sought to evaluate the impact on LV function of high-dose bolus tirofiban or abciximab in patients undergoing primary PCI with the predictors of favorable (≥50%) LV ejection fraction (EF) and LV function recovery at 30 days. We studied 314 patients (abciximab n = 154; tirofiban n = 160) undergoing primary PCI in the randomized Facilitated Angioplasty with Tirofiban or Abciximab (FATA) trial. LVEF was assessed within 48 hours and at 30 days after primary PCI. In patients with systolic dysfunction at baseline, LV function recovery was defined by either increase of LVEF ≥10% compared with baseline or LVEF ≥50%. Similar LVEF was observed in the 2 groups postprocedure (abciximab 49.7 ± 10.1% vs tirofiban 49.3 ± 10.1%, p = 0.9) and at 30 days (abciximab 53.1 ± 9.8% vs tirofiban 52.5 ± 10.2%, p = 0.6). Independent predictors of 30-day LVEF ≥50% were preprocedure Thrombolysis In Myocardial Infarction flow class >0 (odds ratio = 2.4, 95% confidence interval 1.32 to 4.34), anterior location (odds ratio = 0.25, 95% confidence interval 0.15 to 0.42), and age (odds ratio = 0.97, 95% confidence interval 0.95 to 0.99). Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 was the only predictor of LV function recovery (odds ratio = 6.73, 95% confidence interval 2.69 to 16.88). In conclusion, this study showed no difference in LV function recovery in patients undergoing primary PCI treated either with abciximab or high-dose bolus tirofiban. Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 seems to be the most important predictor of favorable LVEF and LV function recovery at 30 days.</description><subject>Aged</subject><subject>Angioplasty, Balloon, Coronary</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Combined Modality Therapy</subject><subject>Coronary heart disease</subject><subject>Coronary vessels</subject><subject>Diseases of the cardiovascular system</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - pharmacology</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - therapy</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Pharmacology</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Treatment Outcome</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - pharmacology</subject><subject>Tyrosine - therapeutic use</subject><subject>Ventricular Function, Left - drug effects</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksGO0zAQhiMEYpeFRwBZSCA4pNhJHccXUFRtoVIRlbbAASHLdcasS2oX2yn0oXkHnG21lfbCybLz_f9MZv4se0rwiGBSvVmP5GatpG9HBcb1iJARLvi97JzUjOeEk_J-do4xLnJOxvwsexTCOl0JodXD7IzwoqpZWZxnf-egI_oCNnqj-k56NO2tisZZ1OgIHl0t88sOdvLm6ePeDSWN7NDMaukPoLFokb4nj4CWHmSEFn018RotvNlIv0cL8KqP0oLrA5o47-zwOrPJf5dUg4e0LWpWyvxJihVyHi2Nd9qspEWvtHcbFK8BTaUynYk3BRr7w7htJ0Pco99DsZMgqU9W36bNsvme-kpNv36cPdCyC_DkeF5kn6eXy8mHfP7p_WzSzHM1ZjTmwErJKdUVU4ySusSV0nLFaoprRRRjDIDTijKJx22apK6gpbRtoeRaF3VFyovs5cF3692vHkIUGxMUdN1hBqJiaReMVwl8fgdcu97b1JsoSlxyRmiRIHqAlHcheNBiexisIFgMYRBrcQyDGMIgCBEpDEn37GjerzbQnlTH7SfgxRGQQclOe2mVCbdcQYqaczZw7w4cpJntDHgRVFq3gtZ4UFG0zvy3lbd3HFRnrElFf8Iewu1PExEKgcXVkNwhuLjGBa7HtPwHZg3uJA</recordid><startdate>20090315</startdate><enddate>20090315</enddate><creator>Taglieri, Nevio, MD</creator><creator>Saia, Francesco, MD, PhD</creator><creator>Guiducci, Vincenzo, MD</creator><creator>Tondi, Stefano, MD</creator><creator>Conrotto, Federico, MD</creator><creator>Marrozzini, Cinzia, MD</creator><creator>Rocchi, Guido, MD</creator><creator>Biagini, Elena, MD, PhD</creator><creator>Reggiani, Maria Letizia Bacchi, MSc</creator><creator>Giacometti, Paola, MD</creator><creator>Piovaccari, Giancarlo, MD</creator><creator>Manari, Antonio, MD</creator><creator>Marzocchi, Antonio, MD</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20090315</creationdate><title>Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial)</title><author>Taglieri, Nevio, MD ; Saia, Francesco, MD, PhD ; Guiducci, Vincenzo, MD ; Tondi, Stefano, MD ; Conrotto, Federico, MD ; Marrozzini, Cinzia, MD ; Rocchi, Guido, MD ; Biagini, Elena, MD, PhD ; Reggiani, Maria Letizia Bacchi, MSc ; Giacometti, Paola, MD ; Piovaccari, Giancarlo, MD ; Manari, Antonio, MD ; Marzocchi, Antonio, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-e73a955f67c7518306cfab78508c1c777ee95657a04d926f6ed55dde39ff28613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Angioplasty, Balloon, Coronary</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Combined Modality Therapy</topic><topic>Coronary heart disease</topic><topic>Coronary vessels</topic><topic>Diseases of the cardiovascular system</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - pharmacology</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - therapy</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Pharmacology</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Treatment Outcome</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - pharmacology</topic><topic>Tyrosine - therapeutic use</topic><topic>Ventricular Function, Left - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taglieri, Nevio, MD</creatorcontrib><creatorcontrib>Saia, Francesco, MD, PhD</creatorcontrib><creatorcontrib>Guiducci, Vincenzo, MD</creatorcontrib><creatorcontrib>Tondi, Stefano, MD</creatorcontrib><creatorcontrib>Conrotto, Federico, MD</creatorcontrib><creatorcontrib>Marrozzini, Cinzia, MD</creatorcontrib><creatorcontrib>Rocchi, Guido, MD</creatorcontrib><creatorcontrib>Biagini, Elena, MD, PhD</creatorcontrib><creatorcontrib>Reggiani, Maria Letizia Bacchi, MSc</creatorcontrib><creatorcontrib>Giacometti, Paola, MD</creatorcontrib><creatorcontrib>Piovaccari, Giancarlo, MD</creatorcontrib><creatorcontrib>Manari, Antonio, MD</creatorcontrib><creatorcontrib>Marzocchi, Antonio, MD</creatorcontrib><creatorcontrib>FATA Investigators</creatorcontrib><creatorcontrib>FATA Trial Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taglieri, Nevio, MD</au><au>Saia, Francesco, MD, PhD</au><au>Guiducci, Vincenzo, MD</au><au>Tondi, Stefano, MD</au><au>Conrotto, Federico, MD</au><au>Marrozzini, Cinzia, MD</au><au>Rocchi, Guido, MD</au><au>Biagini, Elena, MD, PhD</au><au>Reggiani, Maria Letizia Bacchi, MSc</au><au>Giacometti, Paola, MD</au><au>Piovaccari, Giancarlo, MD</au><au>Manari, Antonio, MD</au><au>Marzocchi, Antonio, MD</au><aucorp>FATA Investigators</aucorp><aucorp>FATA Trial Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2009-03-15</date><risdate>2009</risdate><volume>103</volume><issue>6</issue><spage>785</spage><epage>790</epage><pages>785-790</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Abciximab therapy during primary percutaneous coronary intervention (PCI) has shown to ameliorate left ventricular (LV) function recovery in patients with ST elevated myocardial infarction. High-dose bolus tirofiban has similar effect on platelet inhibition. Whether this is associated with comparable efficacy on LV function recovery remains unclear. We sought to evaluate the impact on LV function of high-dose bolus tirofiban or abciximab in patients undergoing primary PCI with the predictors of favorable (≥50%) LV ejection fraction (EF) and LV function recovery at 30 days. We studied 314 patients (abciximab n = 154; tirofiban n = 160) undergoing primary PCI in the randomized Facilitated Angioplasty with Tirofiban or Abciximab (FATA) trial. LVEF was assessed within 48 hours and at 30 days after primary PCI. In patients with systolic dysfunction at baseline, LV function recovery was defined by either increase of LVEF ≥10% compared with baseline or LVEF ≥50%. Similar LVEF was observed in the 2 groups postprocedure (abciximab 49.7 ± 10.1% vs tirofiban 49.3 ± 10.1%, p = 0.9) and at 30 days (abciximab 53.1 ± 9.8% vs tirofiban 52.5 ± 10.2%, p = 0.6). Independent predictors of 30-day LVEF ≥50% were preprocedure Thrombolysis In Myocardial Infarction flow class >0 (odds ratio = 2.4, 95% confidence interval 1.32 to 4.34), anterior location (odds ratio = 0.25, 95% confidence interval 0.15 to 0.42), and age (odds ratio = 0.97, 95% confidence interval 0.95 to 0.99). Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 was the only predictor of LV function recovery (odds ratio = 6.73, 95% confidence interval 2.69 to 16.88). In conclusion, this study showed no difference in LV function recovery in patients undergoing primary PCI treated either with abciximab or high-dose bolus tirofiban. Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 seems to be the most important predictor of favorable LVEF and LV function recovery at 30 days.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>19268732</pmid><doi>10.1016/j.amjcard.2008.11.029</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2009-03, Vol.103 (6), p.785-790 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67000796 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Angioplasty, Balloon, Coronary Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Biological and medical sciences Cardiology Cardiology. Vascular system Cardiovascular Combined Modality Therapy Coronary heart disease Coronary vessels Diseases of the cardiovascular system Drug dosages Drug therapy Electrocardiography Female Heart Heart attacks Humans Immunoglobulin Fab Fragments - pharmacology Immunoglobulin Fab Fragments - therapeutic use Male Medical sciences Middle Aged Myocardial Infarction - diagnosis Myocardial Infarction - drug therapy Myocardial Infarction - therapy Myocarditis. Cardiomyopathies Pharmacology Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Treatment Outcome Tyrosine - analogs & derivatives Tyrosine - pharmacology Tyrosine - therapeutic use Ventricular Function, Left - drug effects |
| title | Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A41%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Left%20Ventricular%20Function%20After%20ST-Elevation%20Myocardial%20Infarction%20in%20Patients%20Treated%20With%20Primary%20Percutaneous%20Coronary%20Intervention%20and%20Abciximab%20or%20Tirofiban%20(from%20the%20Facilitated%20Angioplasty%20with%20Tirofiban%20or%20Abciximab%20%5BFATA%5D%20Trial)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Taglieri,%20Nevio,%20MD&rft.aucorp=FATA%20Investigators&rft.date=2009-03-15&rft.volume=103&rft.issue=6&rft.spage=785&rft.epage=790&rft.pages=785-790&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2008.11.029&rft_dat=%3Cproquest_cross%3E1663594631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230397152&rft_id=info:pmid/19268732&rft_els_id=1_s2_0_S0002914908020845&rfr_iscdi=true |